Related references
Note: Only part of the references are listed.CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia
Jyoti Naik et al.
HAEMATOLOGICA (2019)
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
Karen L. Bride et al.
BLOOD (2018)
Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?
Avinash Bonda et al.
BONE MARROW TRANSPLANTATION (2018)
Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia
Chezi Ganzel et al.
HAEMATOLOGICA (2018)
Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia
Chezi Ganzel et al.
HAEMATOLOGICA (2018)
Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation
Claudia I. Chapuy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation
Nicola Goekbuget et al.
BLOOD (2011)
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801
Daniel J. DeAngelo et al.
BLOOD (2007)
Share Paper
